Deciphera Pharmaceuticals Aktie [WKN DE: A2H48H / ISIN: US24344T1016]

Kurse + Charts + Realtime		News + Analysen	Fundamental	Unternehmen	zugeh. Wertpapiere	Aktion
Kurs + Chart	Chart (groß)	News + Adhoc	Bilanz/GuV	Termine	Zertifikate	Portfolio
Times + Sales	Chartvergleich	Analysen	Schätzungen	Profil	Optionsscheine	Watchlist
Börsenplätze	Realtime Push	Kursziele	Dividende/GV	Knock-Outs
Analysen

Kurse + Charts + Realtime
Kurs + Chart
Times + Sales
Börsenplätze

News + Analysen
News + Adhoc
Analysen
Kursziele

Fundamental
Bilanz/GuV
Schätzungen
Dividende/GV
Analysen

Unternehmen
Termine
Profil

zugeh. Wertpapiere
Zertifikate
Optionsscheine
Knock-Outs

Nachrichten zu Deciphera Pharmaceuticals Inc Registered Shs

29.04.24		Deciphera Up In Pre-market On News Of Acquisition By ONO Pharmaceutical For About $2.4 Bln (RTTNews)
29.04.24		ONO To Acquire Deciphera; Total Equity Value Of Deal At Approx. $2.4 Bln (RTTNews)
06.02.24		Deciphera Pharmaceuticals, Inc. Q4 Loss beats estimates (RTTNews)
30.10.23		Deciphera Pharmaceuticals, Inc. Q3 Loss increases, but beats estimates (RTTNews)
30.10.23		Deciphera Reports Positive Results From MOTION Phase 3 Study Of Vimseltinib In TGCT (RTTNews)
20.01.23		Deciphera Pharma Prices Public Offering Of 6.94 Mln Shares At $18/shr (RTTNews)
12.09.22		Deciphera Presents Updated Phase 1/2 Data For Vimseltinib In Tenosynovial Giant Cell Tumor AT ESMO (RTTNews)
02.06.22		Deciphera Pharmaceuticals, Inc. to Participate in Upcoming Investor Conferences (Businesswire)
04.05.22		Deciphera Pharmaceuticals, Inc. Announces First Quarter 2022 Financial Results (Businesswire)
02.05.22		Deciphera Pharmaceuticals to Announce First Quarter 2022 Financial Results and Host Conference Call and Webcast on May 4, 2022 (Businesswire)
29.04.22		Deciphera Pharmaceuticals Announces Closing of Public Offering of Common Stock and Pre-funded Warrants and Full Exercise of Underwriters' Option to Purchase Additional Shares (Businesswire)
27.04.22		Deciphera Pharmaceuticals Announces Pricing of Public Offering of Common Stock and Pre-funded Warrants (Businesswire)
26.04.22		Deciphera Pharmaceuticals Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants (Businesswire)
09.03.22		Deciphera Pharmaceuticals, Inc. to Present at the Barclays Global Healthcare Conference (Businesswire)
08.02.22		Deciphera Pharmaceuticals, Inc. Announces Fourth Quarter and Full Year 2021 Financial Results (Businesswire)
02.02.22		Deciphera Pharmaceuticals, Inc. to Present at Upcoming Investor Conferences (Businesswire)
01.02.22		Deciphera Pharmaceuticals to Announce Fourth Quarter and Full Year 2021 Financial Results and Host Conference Call and Webcast on February 8, 2022 (Businesswire)
24.01.22		Deciphera Pharmaceuticals Presents Results from the INTRIGUE Phase 3 Clinical Study at the American Society of Clinical Oncology Plenary Series Session (Businesswire)
03.01.22		Deciphera Pharmaceuticals, Inc. to Present at the 40th Annual J.P. Morgan Healthcare Conference (Businesswire)
21.12.21		Deciphera Pharma Reports Approval Of QINLOCK In The UK - Quick Facts (RTTNews)
30.11.21		Deciphera Pharma Announces Corporate Restructuring; To Cut About 140 Positions - Quick Facts (RTTNews)
22.11.21		EU Approves Deciphera's Qinlock For Advanced Gastrointestinal Stromal Tumor Treatment (RTTNews)
05.11.21		Deciphera's INTRIGUE Phase 3 Clinical Study Fails To Yield Expected Result (RTTNews)
12.10.21		Deciphera Pharma Reports Approval Of QINLOCK In Switzerland - Quick Facts (RTTNews)
17.09.21		CHMP Adopts Positive Opinion For Deciphera's Qinlock To Treat Gastrointestinal Stromal Tumor (RTTNews)
30.06.21		Deciphera Announces First Patient Treated in Phase 1 Study of DCC-3116 in Patients with Advanced or Metastatic Tumors with a Mutant RAS or RAF Gene (Businesswire)
27.05.21		Deciphera Pharmaceuticals, Inc. to Present at Upcoming Investor Conferences (Businesswire)
04.05.21		Deciphera Pharmaceuticals, Inc. Announces First Quarter 2021 Financial Results (Businesswire)
27.04.21		Deciphera Pharmaceuticals to Announce First Quarter 2021 Financial Results and Host Conference Call and Webcast on May 4, 2021 (Businesswire)
02.03.21		Deciphera Pharmaceuticals, Inc. to Present at the Barclays Global Healthcare Conference (Businesswire)
18.02.21		Deciphera Pharmaceuticals, Inc. to Present at the SVB Leerink 10th Annual Global Healthcare Conference (Businesswire)
09.02.21		Deciphera Pharmaceuticals, Inc. Announces Fourth Quarter and Full Year 2020 Financial Results (Businesswire)
04.02.21		Deciphera Pharmaceuticals, Inc. to Present at the Guggenheim Healthcare Talks 2021 Idea Forum Oncology Day (Businesswire)
02.02.21		Deciphera Pharmaceuticals to Announce Fourth Quarter and Full Year 2020 Financial Results and Host Conference Call and Webcast on February 9, 2021 (Businesswire)
11.01.21		Deciphera Pharmaceuticals Provides Corporate Update and Highlights Key 2021 Corporate Milestones (Businesswire)
05.01.21		Deciphera Pharmaceuticals to Present at the 39th Annual J.P. Morgan Healthcare Conference (Businesswire)
30.11.20		Deciphera Pharmaceuticals Completes Target Enrollment in the INTRIGUE Phase 3 Clinical Study of QINLOCK® (Ripretinib) in Patients with Second-Line Gastrointestinal Stromal Tumor (Businesswire)
24.11.20		Deciphera Pharmaceuticals, Inc. to Participate in the Piper Sandler 32nd Annual Virtual Healthcare Conference (Businesswire)
23.11.20		The Boston Globe Names Deciphera a Top Place to Work for 2020 (Businesswire)
11.11.20		Deciphera Presents Data from QINLOCK® (Ripretinib) Program at the Connective Tissue Oncology Society (CTOS) 2020 Virtual Annual Meeting (Businesswire)
10.11.20		Deciphera Pharmaceuticals, Inc. to Present at the Jefferies Virtual London Healthcare Conference (Businesswire)
05.11.20		Deciphera Pharmaceuticals, Inc. Announces Third Quarter 2020 Financial Results (Businesswire)
28.10.20		Deciphera Pharmaceuticals, Inc. to Announce Third Quarter 2020 Financial Results and Host Conference Call and Webcast on November 5, 2020 (Businesswire)
18.09.20		Deciphera Presents Data from QINLOCK™ (Ripretinib) Program in Patients with Gastrointestinal Stromal Tumor at the European Society for Medical Oncology (ESMO) Virtual Congress 2020 (Businesswire)
17.08.20		Deciphera Announces Publication of QINLOCK™ (ripretinib) Phase 1 Study Results in Patients with Gastrointestinal Stromal Tumor in Journal of Clinical Oncology (Businesswire)
13.02.20		ADXS, TROV On Watch, NRBO Soars 95%, DCPH To Face FDA In Aug. (RTTNews)
14.08.19		5 Top Gainers In Healthcare Sector (DCPH, MBIO, BCEL...) (RTTNews)
13.08.19		Top 5 Losers In Healthcare Sector (CTST, PGNX, DCPH…) (RTTNews)
02.08.19		Catalysts Ahead: Will These 4 Pharma Stocks Hit Or Miss The Mark? (RTTNews)
24.06.19		Mark Your Calendar: These 4 Pharma Stocks Are Prepping For The Big Day (RTTNews)

1 | Weiter

Newssuche

Meistgelesene Nachrichten

Pierer Mobility-Aktie schwach: Gehälter für Angestellte von insolventer KTM noch vor Weihnachten

UNIQA Insurance-Aktie im Plus: UNIQA plant zu expandieren und Dividenden zu erhöhen

Ethereum Kurs Prognose: ETH massiv unterbewertet! Fällt jetzt das ATH?

Bundesheer wirbt nach KTM-Insolvenz um Mitarbeiter - Pierer Mobility-Aktie im Plus

EZB wird wohl Leitzinsen senken - wie stark?

OMV-Aktie verliert: OMV kündigt Liefervertrag mit Gazprom

finanzen.net Apps

ETF-Sparplan

Oskar ist der einfache und intelligente ETF-Sparplan. Er übernimmt die ETF-Auswahl, ist steuersmart, transparent und kostengünstig.

JETZT MEHR ERFAHREN

Aktien ATX DAX EuroStoxx 50 Dow Jones NASDAQ 100 Nikkei 225 S&P 500

Kontakt - Impressum - Werbung

Sitemap - Datenschutz - Disclaimer - AGB - Privatsphäre-Einstellungen

Für die aufgeführten Inhalte kann keine Gewährleistung für die Vollständigkeit, Richtigkeit und Genauigkeit übernommen werden.
Kursinformationen von SIX Financial Information Deutschland GmbH. Verzögerung 15 Min. (Nasdaq, NYSE: 20 Min.).
© 1999-2024 finanzen.net GmbH

*Werbehinweise: Die Billigung des Basisprospekts durch die Bundesanstalt für Finanzdienstleistungsaufsicht ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.

⁵Hinweis zu Plus500: 82% der Kleinanlegerkonten verlieren Geld beim CFD-Handel mit diesem Anbieter. Sie sollten überlegen, ob Sie es sich leisten können, das hohe Risiko einzugehen, Ihr Geld zu verlieren. Plus500UK Ltd ist zugelassen und reguliert durch Financial Conduct Authority (FRN 509909). Plus500CY Ltd authorized & regulated by CySEC (#250/14).

Währungsrechner News Devisen Dollarkurs Aktienkurse Bitcoin Rohstoffe Fonds

Portfolioname: Watchlistname:
Portfolio:
Name:
Typ:
ISIN:
Börse:
Anzahl:
Aktueller Kurs:
Kurszeit:
Kaufpreis:
Kaufdatum:	15.12.2024 08:47
Kaufwert:	EUR
	Hinzufügen Speichern